Acute Myelogenous Lymphoma (AML)

Relapsed/Refractory disease after 1+ lines
- CCT5027 Phase I FLT3 Chimeric AntigenReceptor T-Cell(CAR-T) AMG 553 in FLT3-Positive Relapsed/Refractory AML PI: Muffy Pending

First (CR1)/Second (CR2) Remission
- BMT330 Phase II Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT PI: Muffy Sponsor: Stanford
- BMT302 Phase II Ibrutinib Maintenance After Reduced-Intensity Conditioning &Allogeneic HCT in AcuteLeukemia PI: Rezvani Stanford

Advanced Disease
- FLT3 Mutation
  - BMT332 Phase III FLT3Inhibitor Ibrutinib Maintenance Therapy After Allogeneic Transplant in FLT3/ITD AML PI: Muffy BMT CTN
  - BMT334 Gilteritinib (ASP2215) in FLT3 Mutated Relapsed or Refractory AML or FLT3-Mutated AML in CR w/ MRD PI: Muffy Pending

First(CR1) or Higher Remission
- Matched Related Donor
- Matched Related or Unrelated Donor
- Haplo
  - BMT338 Phase I DonorGrafts DerivedFrom OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies PI: Meyer NIH Sponsor: Orca Biosystems
  - BMT326 Phase III Haploidentical HSCT &ATIR101 or Post-Transplant Cyclophosphamide in Hematologic Malignancy PI: Johnson Pending

KEY
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu